Blog: INHIBIKASE THERAPEUTICS, INC. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K) –

Item 7.01 Regulation FD Disclosure.

On September 16, 2022, Inhibikase Therapeutics, Inc. (the “Company”) made a
conference presentation at the International Congress of Parkinson’s Disease and
Movement Disorders® in Madrid, Spain. A copy of the Company’s presentation is
attached hereto as Exhibit 99.1 and is incorporated herein by reference.

The information contained in this Current Report on Form 8-K speaks only as of
the date hereof. While the Company may elect to update the information in this
Current Report on Form 8-K in the future, the Company disclaims any obligation
to do so except to the extent required by applicable law.

The information furnished in this Item 7.01 of this Current Report on
Form 8-K and Exhibit 99.1 attached hereto shall not be deemed “filed” for the
purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the
“Exchange Act”), or otherwise subject to the liabilities of that section. The
information in this Item 7.01 of this Current Report on Form 8-K is not
incorporated by reference into any filings of the Company made under the
Securities Act of 1933, as amended, or the Exchange Act, whether made before or
after the date of this Current Report on Form 8-K, regardless of any general
incorporation language in the filing unless specifically stated so therein.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Number      Description

99.1          Conference Presentation of Inhibikase Therapeutics, Inc.

104         Cover Page Interactive Data File (embedded within the Inline XBRL


© Edgar Online, source Glimpses

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s